Carly P. Smith, PhD and Daniel R. George, PhD, MSc
Invisibility of racial inequity and gender inclusion in clinical research means key features of disease etiology and symptom presentation are unaccounted for.
AMA J Ethics. 2021;23(7):E563-568. doi:
10.1001/amajethics.2021.563.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Dr Daphne Mlachila joins Ethics Talk to discuss her article: “How Should Clinicians and Researchers in Government Respond to Threats to Their Offices?”
Professor Wendy E. Parmet joins Ethics Talk to discuss her article, coauthored with Dr Claudia E. Haupt: “Holding Clinicians in Public Office Accountable to Professional Standards.”
Dr Isabelle Freiling joins Ethics Talk to discuss her article, coauthored with Nicole M. Krause and Dr Dietram A. Scheufele: “Science and Ethics of ‘Curing’ Misinformation.”